Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life

Gheath Alatrash, Marcos De Lima, Nelson Hamerschlak, Matteo Pelosini, Xuemei Wang, Lianchun Xiao, Fabio Kerbauy, Alexandre Chiattone, Gabriela Rondon, Muzaffar H. Qazilbash, Sergio A. Giralt, Leandro De Padua Silva, Chitra Hosing, Partow Kebriaei, Weiqing Zhang, Yago Nieto, Rima M. Saliba, Richard E. Champlin, Borje S. Andersson

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Fingerprint

Dive into the research topics of 'Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life'. Together they form a unique fingerprint.

Medicine & Life Sciences